** Shares of Clarity Pharmaceuticals CU6.AX up ~2% at A$4.135, set for a fourth consecutive session of gain
** Radiopharma co says the U.S. Food and Drug Administration has granted Fast Track Designation for its prostate cancer drug, 64Cu-SAR-bisPSMA
** Says the drug has several advantages over currently approved ones, including improved diagnostic performance and flexible imaging schedule, among others
** Stock rises as much as 15.5% earlier in the day, marking its biggest intraday pct gain since Dec. 18, 2024
** About 2 mln shares change hands, 1.1x the 30-avg
** Stock more than doubled in value last year
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.